Results 171 to 180 of about 8,720 (195)

Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1

British Journal of Clinical Pharmacology, 2010
Yong-Bok Lee, Hea-Young Cho
exaly  

Cilostazol

Reactions Weekly, 2009
openaire   +1 more source

Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence

Atherosclerosis, 2001
Michio Otsuki, Sôji Kasayama, Haruhiko Kouhara   +2 more
exaly  

Analogues of cilostazol

2008
LIU JULIE F, PERSICHETTI ROSE A
openaire   +3 more sources

Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats

Atherosclerosis, 2000
Takeshi Tani
exaly  

CILOSTAZOL PREPARATION

2000
MUKAI TADASHI, TOMOHIRA YUSO, TODA MASAFUMI, YAMADA KEIGO, OKA YOSHIKAZU   +4 more
openaire   +3 more sources

Cilostazol

Reactions Weekly
openaire   +1 more source

In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

Human and Experimental Toxicology, 2000
Richat Abbas, S L Bramer, D A Flockhart
exaly  

Analogues of cilostazol

2010
PERSICHETTI ROSE A, LIU JULIE F, MASSE CRAIG E, HARBESON SCOTT L   +3 more
openaire   +3 more sources

Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics

Clinical Pharmacokinetics, 2012
Steven L Bramer, William P Forbes, S L Bramer   +2 more
exaly